

TABLE OF CONTENTS

ABSTRACT	i
ABSTRAK	iv
ACKNOWLEDGEMENT	viii
TABLE OF CONTENTS	x
LIST OF ABBREVIATIONS	xv
LIST OF TABLES	xvii
LIST OF FIGURES	xix
 CHAPTER 1 - INTRODUCTION		 1
 CHAPTER 2 - LITERATURE REVIEW	 	
2.1 The Cervix	5
2.1.1 Anatomy of the Cervix	5
2.1.2 Normal Histology	6
2.2 Cervical cancer	7
2.2.1 Preinvasive cervical lesions	7
2.2.2 International classification of cervical carcinoma	8
2.2.3 Histological types of cervical carcinoma	11
2.2.4 Pathology of cervical carcinoma	11
2.2.5 Spread of the tumour	11
2.2.6 Clinical symptoms	12
2.3 Treatment and Prevention	13
2.3.1 Methods of diagnosis	13
2.3.2 Treatment of CIN/CIS	14
2.3.3 Treatment of cervical carcinoma	15
2.4 Epidemiology of cervical cancer	16
2.4.1 Age at first sexual intercourse	16
2.4.2 Number of sexual partners	16
2.4.3 Parity	17
2.4.4 Characteristics of the male sexual partner	18
2.4.5 Socioeconomic status	19
2.4.6 Cigarette smoking	19
2.4.7 Nutrition	20
2.4.8 Oral contraceptive	21
2.5 Papillomaviruses	22
2.5.1 Genome structure and organization	23
2.5.2 Viral transcription	27
2.5.3 Viral replication	30
2.5.4 Classification of human papillomaviruses	31

2.5.5	Clinical manifestations of HPV infections	31
2.5.6	HPV infections of the genital tract	35
2.5.7	HPV and cervical carcinoma	36
2.6	Immune response to HPV	38
2.6.1	Humoral response	38
2.6.1.1	Synthetic peptides	40
2.6.1.2	Fusion proteins	41
2.6.2	Cell mediated immunity	42
2.6.2.1	Natural killer (NK) cells	43
2.6.2.2	Langerhans' cells	44
2.6.2.3	T cell response	45
2.7	Detection of papillomavirus infection	46
2.7.1	Clinical examination	46
2.7.2	Nucleic acid hybridization	47
2.7.2.1	Southern blot hybridization	48
2.7.2.2	In situ hybridization	49
2.7.2.3	Non-radioactive probe	49
2.7.3	Polymerase chain reaction technique (PCR)	51
2.7.4	Enzyme-Linked Immunosorbent Assay (ELISA)	53
2.7.5	Immunohistochemistry	54

CHAPTER 3 - MATERIALS AND METHODS

3.1	Detection of HPV 16 and 18 DNA in clinical samples	56
3.1.1	Clinical samples	56
3.1.1.1	Fresh frozen invasive cervical carcinoma biopsies	56
3.1.1.2	Cervical scrapes	56
3.1.1.3	Noncervical DNA samples	57
3.1.2	Primers used for the amplification of the β -globin gene	57
3.1.3	Degenerate primers used for the amplification of HPV sequences	57
3.1.4	Plasmids	58
3.1.4.1	Plasmids isolation	59
3.1.5	Cell lines	60
3.1.5.1	Reviving and culturing of cells	60
3.1.5.2	Cryopreservation of cells	61
3.1.6	DNA extraction	61
3.1.6.1	Quantification of DNA samples	62
3.1.7	Polymerase chain reaction	63
3.1.7.1	PCR amplification of the β -globin gene	63
3.2.7.2	PCR amplification of the HPV DNA	64
3.1.8	Agarose gel electrophoresis	65
3.1.9	Non-radioactive HPV DNA probe preparation and labelling	66
3.1.10	Southern transfer of PCR amplified products	67
3.1.11	Non-radioactive hybridization	68
3.1.12	Detection of hybrids on nylon membranes	69

3.2	Detection of HPV 16 and 18 DNA by in situ hybridization	70
3.2.1	Paraffin embedded cervical biopsies	70
3.2.2	Pretreatment of slides	70
3.2.3	Culturing cell lines on slides	71
3.2.4	In situ hybridization	72
3.2.5	Detection of hybrids on slides	73
3.2.6	Statistical analysis	74
3.3	Detection of HPV proteins	74
3.3.1	Monoclonal antibodies	74
3.3.2	Immunohistochemistry	74
3.3.3	Statistical analysis	76
3.4	Serology to HPV	76
3.4.1	Peptides	76
3.4.2	Blood samples	76
3.4.3	Enzyme-Linked Immunosorbent Assay	77
3.4.4	Statistical analysis	79

CHAPTER 4 - RESULTS

4.1	Detection of HPV DNA by PCR and Southern blot hybridization	80
4.1.1	PCR amplification of HPV DNA extracted from cervical carcinoma biopsy tissues	80
4.1.2	Southern blot hybridization typing of HPV DNA from cervical carcinoma biopsy tissues	81
4.1.3	PCR amplification of HPV DNA from normal cervical scrapes	81
4.1.4	Southern blot hybridization typing of HPV from normal cervical scrapes	82
4.1.5	PCR amplification of HPV DNA from non-cervical specimens	82
4.1.6	Southern blot hybridization typing of HPV DNA from non-cervical specimens	82
4.1.7	Controls for PCR and Southern blot hybridization	83
✓ 4.2	(In situ hybridization detection of HPV 16 and HPV 18 in cervical lesions	89
4.2.1	Detection of HPV 16 and 18 DNA in CIN 1	89
4.2.2	Detection of HPV 16 and 18 DNA in CIN 2	89
4.2.3	Detection of HPV 16 and 18 DNA in CIN 3/CIS	90
4.2.4	Detection of HPV 16 and 18 DNA in invasive cervical carcinomas)	90
4.3	Prevalence of HPV 16 and 18 DNA in CIN and invasive cervical lesions as detected by PCR, Southern blot hybridization and in situ hybridization	91
4.3.1	Occurrence of single and mixed infections with HPV 16 and 18 in cervical lesions	92
4.3.2	Age of patients at diagnosis and histologic features of cervical lesions	93

4.3.3	Prevalence of HPV DNA and age of patients	93
✓ 4.4	Detection of HPV antigens by immunohistochemistry	104
4.4.1	Correlation between cervical histology and the detection frequencies of HPV 18 E6 protein	104
4.4.1.1	Correlation between the expression of E6 protein and the presence of HPV 18 DNA	105
4.4.1.2	Topographical distribution of HPV 18 E6 protein in cervical lesions	105
4.4.1.3	Distribution of HPV 18 E6 protein in CIN 2	106
4.4.1.4	Distribution of HPV 18 E6 protein in CIN 3/CIS	106
4.4.1.5	Distribution of HPV 18 E6 protein in invasive carcinoma	107
4.4.1.6	Intracellular localization of HPV 16 E6 protein in CIN and invasive carcinoma)	107
4.4.2	Correlation between cervical histology and the detection frequencies of HPV 16 L1 protein	115
4.4.2.1	Correlation between the expression of the HPV 16 L1 protein and the presence of HPV 16 DNA	116
4.4.2.2	Topographical distribution of HPV 16 L1 protein in cervical lesions	116
4.4.2.3	Distribution of HPV 16 L1 protein in CIN 1	117
4.4.2.4	Distribution of HPV 16 L1 protein in CIN 2	118
4.4.2.5	Distribution of HPV 16 L1 protein in CIN 3/CIS	118
4.4.2.6	Distribution of HPV 16 L1 protein in invasive carcinoma	118
4.5	Serology to HPV	127
4.5.1	Immune response to HPV 16 L1:13 peptide	127
4.5.2	Immune response to HPV 16 L1:30 peptide	134
4.5.3	Immune response to HPV 16 L2:49 peptide	140
4.5.4	Immune response to HPV 16 E2:245 peptide	146
4.5.5	Immune response to HPV 16 E7:5 peptide	152
4.5.6	Immune response to HPV 18 E2:245 peptide	158

CHAPTER 5 - DISCUSSION

5.1	Polymerase chain reaction and Southern blot hybridization	164
5.2	In situ hybridization	168
5.2.1	Distribution of HPV DNA within CIN lesions as detected by in situ hybridization	170
5.2.2	Distribution of HPV DNA within invasive cervical lesions as detected by in situ hybridization	172
5.3	Prevalence of HPV 16 and 18 in cervical lesions as determined by in situ hybridization and PCR-Southern blot hybridization	173
5.3.1	Prevalence of HPV 16 and 18 in CIN	173
5.3.2	Prevalence of HPV 16 and 18 DNA in invasive carcinoma	177
5.3.3	HPV genotype and cell patterns	179
5.3.4	Occurrence of mixed infections in cervical lesions	180

5.3.5	HPV-negative invasive carcinoma	182
5.3.6	Age of patients at diagnosis and histologic of cervical lesions	183
5.3.7	Prevalence of HPV 16 and 18 in relation to the age of patients	183
5.3.8	Detection of HPV 16 and 18 DNA in normal cervical scrapes	184
5.4	Immunohistochemical detection of HPV antigens	187
5.4.1	Detection HPV 18 E6 antigen in cervical lesions	187
5.4.1.1	Distribution of HPV 18 E6 protein in CIN	188
5.4.1.2	Distribution of HPV 18 E6 protein in cervical cancer	190
5.4.2	Detection of HPV 16 L1 protein in cervical lesions	193
5.4.2.1	Detection of HPV 16 L1 protein in CIN	193
5.4.2.2	Detection of HPV 16 L1 protein in invasive carcinoma	195
5.5	Serology to HPV	199
5.5.1	Immune response to HPV 16 L1:13 and L1:30 peptides	201
5.5.2	Immune response to the L2 peptide	202
5.5.3	Immune response to HPV 16 E7:5 peptide	204
5.5.4	Immune response to HPV 16 and 18 E2:245 peptide	206
5.5.5	Immune response of pregnant women to HPV antigen	209
5.5.6	Immune response of healthy university students to HPV antigens	212
CHAPTER 6 - CONCLUSION		 214
BIBLIOGRAPHY		 218
APPENDIX		 252

LIST OF ABBREVIATIONS

%	:	percentage
μ	:	micron
°C	:	degree centigrade
μg	:	microgram
μl	:	microlitre
bp	:	base pair
CIN	:	cervical intraepithelial neoplasia
CIS	:	carcinoma in situ
cm	:	centimeter
dATP	:	deoxyadenosine triphosphate
dCTP	:	deoxycytidine triphosphate
ddH ₂ O	:	deionized distilled water
dGTP	:	deoxyguanosine triphosphate
DIG	:	digoxigenin
DNA	:	deoxyribonuclease
dNTP	:	deoxynucleotide triphosphate
dTTP	:	deoxythymidine triphosphate
EDTA	:	ethylenediamine tetraacetic acid
ELISA	:	enzyme-linked immunosorbent acid
g	:	gram
HEPES	:	hydroxyethylpiperazine ethanesulfonic acid
kb	:	kilobase
M	:	molar
mg	:	milligram
ml	:	millilitre
MOPs	:	3-N-morpholino-propanesulfonic acid
NBT	:	4-nitroblue tetrazolium chloride
ng	:	nanogram
PBS	:	phosphate buffered saline
RNase	:	ribonuclease

rpm	:	revolution per minute
SCC	:	squamous cell carcinoma
SDS	:	sodium dodecyl sulphate
TBE	:	tris-borate-EDTA
UV	:	ultraviolet
w/v	:	weight per volume
WHO	:	World Health Organization
CO ₂	:	carbon dioxide
FCS	:	fetal calf serum
OD	:	optical density
nm	:	nanometer
PCR	:	polymerase chain reaction
pmole	:	picomole
U	:	units
ADC	:	adenocarcinoma
CS	:	lamb serum
PBS-T	:	phosphate buffered saline-tween
PCR-SB	:	polymerase chain reaction-Southern blot hybridization
ISH	:	in situ hybridization
ORF	:	open reading frame
FIGO	:	Federation of Gynaecology and Obstetrics
HPV	:	human papillomavirus
E	:	early region
L	:	late region
LCR	:	long control region
kDa	:	kilodalton
BPV	:	bovine papillomavirus
RNA	:	ribonucleic acid
MHC	:	major histocompatibility complex
NK	:	natural killer cells
Tm	:	melting point

LIST OF TABLES

Tables	Subjects	Page
2.1.	Distribution of HPV types by the degree of genetic relatedness	33
2.2.	The human papillomavirus-induced cutaneous and mucosal lesions	34
3.1.	Reaction mix for the amplification of β -globin sequences in the DNA obtained from fresh frozen biopsy tissues, pap smears and noncervical samples	64
3.2.	Reaction mix for the amplification of HPV DNA sequen	64
3.3.	Reaction mix for DNA probe labelling	66
3.4.	Synthetic peptides of HPV 16 and HPV 18	76
4.1.	Distribution of HPV 16 and 18 in various cervical and non-cervical tissues as determined by PCR and Southern blot hybridization	84
4.2.	Distribution of HPV 16 and HPV 18 in CIN lesions as determined by in situ hybridization	94
4.3.	Overall frequency of HPV 16 and HPV 18 DNA in cervical lesions as determined by PCR-Southern blot hybridization (PCR-SB) and in situ hybridization (ISH)	101
4.4.	Distribution of HPV 16 and HPV 18 in preinvasive lesions	102
4.5.	Correlation of age of patients at diagnosis and type of cervical lesions	102
4.6.	Correlation of age of patients at diagnosis and HPV HPV genotype	103
4.7.	Detection of HPV 18 E6 protein in relation to the status of HPV DNA in the cervical intrepithelial neoplasia and cervical cancer	108
4.8.	Intracellular localization of HPV 18 E6 protein cervical lesions as determined by immunohistochemistry	115
4.9.	Detection of HPV 16 L1 protein according to the status of HPV 16 DNA in cervical intraepithelial neoplasia and cervical cancer	120
4.10.	Detection of antibodies against HPV 16 L1:13 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	130
4.11.	Detection of antibodies against HPV 16 L1:30 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	136
4.12.	Detection of antibodies against HPV 16 L2:49 in (a) cervical cancer patients (b) healthy pregnant	

4.13.	women (c) healthy university students Detection of antibodies against HPV 16 E2:245 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	...	142
4.14.	Detection of antibodies against HPV 16 E7:5 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	...	148
4.15.	Detection of antibodies against HPV 18 E2:245 in (a) cervical cancer patients (b) healthy pregnant women (c) healthy university students	...	154
		...	160

LIST OF FIGURES

Figures	Subject	Page
2.1.	Schematic representation of cervical cancer precursors - CIN 1,2, 3 and CIS	10
2.2.	Genomic organization of HPV 16	29
4.1.	Photograph of a 2% agarose gel showing PCR amplified HPV DNA with primers MY11 and MY09	85
4.2.	Photograph of corresponding Southern blot hybridization of PCR amplified product to digoxigenin-labelled HPV 16 DNA probe	86
4.3.	Photograph of a 2% agarose gel showing PCR amplified HPV DNA with primers MY11 and MY09	87
4.4.	Photograph of corresponding Southern blot hybridization of PCR amplified product to digoxigenin-labelled HPV 18 DNA probe	88
4.5.	In situ hybridization analysis of paraffin-embedded CIN 1 tissue using digoxigenin-labelled HPV 16 and 18 DNA probes	95
4.6.	In situ hybridization of HPV 16 and 18 DNA in CIN 2 tissues	96
4.7.	Localization of HPV 16 and HPV 18 DNA in nucleus of cells of CIN 3/CIS tissues	97
4.8.	Presence of HPV DNA in squamous cell carcinoma of the cervix	98
4.9.	DIG detection of HPV 16 genome in HPV-16 carrying CaSki cells fixed onto glass slides	99
4.10.	DIG detection of HPV 18 genome in HPV 18-carrying HeLa cells grown onto glass slides	100
4.11.	Distribution of HPV types according to age groups of patients with cervical lesions	103
4.12.	Correlation between HPV 18 E6 positivity and grades of cervical lesions	109
4.13.	Correlation between the expression of HPV 18 E6 oncoprotein and the detection rate of HPV 18 DNA in CIN lesions and cervical cancer	110
4.14.	Detection of HPV 18 E6 protein in HPV 18-containing HeLa cells using the Labelled Streptavidin Biotin (LSAB) peroxidase, the AEC substrate system and anti-HPV 18 E6 monoclonal antibody (diluted 1:80)	111
4.15.	Immunohistochemical detection of HPV 18 E6 protein in paraffin-embedded CIN 2 tissue	112
4.16.	Detection of HPV 18 E6 protein in cells of CIN 3/CIS	113
4.17.	Localization of HPV 18 E6 protein in the intranuclear and cytoplasmic regions of cells of squamous cell carcinoma	114
4.18.	Correlation between the expression of HPV 16 L1 protein and the detection rate of HPV 16 DNA in	

	CIN lesions and cervical cancer	...	121
4.19.	HPV 16-containing CaSki cells showing no staining to anti-HPV 16 L1 monoclonal antibody (dilution 1:40)	...	122
4.20.	Presence of HPV 16 L1 protein in cells of CIN 2	...	123
4.21.	Distribution of HPV 16 L1 protein in cells of CIN 3/CIS	...	124
4.22a.	Intranuclear localization of HPV 16 L1 protein in cells of adenocarcinoma	...	125
4.22b.	Localization of HPV 16 L1 protein in the nucleus of cells of squamous cell carcinoma	...	126
4.23a.	IgA reactivity to HPV 16 L1:13	...	131
4.23b.	IgG reactivity to HPV 16 L1:13	...	132
4.23c.	IgM reactivity to HPV 16 L1:13	...	133
4.24a.	IgA reactivity to HPV 16 L1:30	...	137
4.24b.	IgG reactivity to HPV 16 L1:30	...	138
4.24c.	IgM reactivity to HPV 16 L1:30	...	139
4.25a.	IgA reactivity to HPV 16 L2:49	...	143
4.25b.	IgG reactivity to HPV 16 L2:49	...	144
4.25c.	IgM reactivity to HPV 16 L2:49	...	145
4.26a.	IgA reactivity to HPV 16 E2:245	...	149
4.26b.	IgG reactivity to HPV 16 E2:245	...	150
4.26c.	IgM reactivity to HPV 16 E2:245	...	151
4.27a.	IgA reactivity to HPV 16 E7:5	...	155
4.27b.	IgG reactivity to HPV 16 E7:5	...	156
4.27c.	IgM reactivity to HPV 16 E7:5	...	157
4.28a.	IgA reactivity to HPV 18 E2:245	...	161
4.28b.	IgG reactivity to HPV 18 E2:245	...	162
4.28c.	IgM reactivity to HPV 18 E2:245	...	163